Factors affecting serum phenobarbital concentration changes in pediatric patients receiving elixir and powder formulations
- PMID: 33526089
- PMCID: PMC7852295
- DOI: 10.1186/s40780-021-00190-2
Factors affecting serum phenobarbital concentration changes in pediatric patients receiving elixir and powder formulations
Abstract
Background: Phenobarbital (PB) is commonly used as elixir and powder formulations in pediatric care. Its dose adjustment is performed based on individual drug concentration monitoring. Few studies have comprehensively analyzed the variation factors for serum PB concentration. In this study, we retrospectively investigated the factors that influence serum PB concentration and assessed the impacts of dosage formulation and administration route.
Methods: This retrospective cohort study covered clinical data from January 2007 to September 2019 at Mie University Hospital. The present study included 60 pediatric patients administered the elixir and powder of PB through oral route and enteral tube. Simple and multiple linear regression analyses were performed to identify the risk factors that affect the weight-corrected PB serum concentration/dose (C/D) ratio in pediatric patients. Six subgroups were also established according to the concomitant use of drugs that potentially inhibit PB metabolism, dosage formulation, and administration route to investigate the difference in the PB C/D ratio among the subgroups.
Results: A significant regression equation to predict the PB C/D ratio was found through simple and multiple linear regression analyses, with an adjusted coefficient of determination of 0.53 (p < 0.001). Further, the concomitant uses of valproic acid (VPA) or amiodarone, which were the only two drugs seen in this study as potential inhibitors of PB, was found to have the greatest effect on the PB C/D ratio (standardized partial regression coefficient (β) = 0.543, p < 0.001). Furthermore, a significant difference in the PB C/D ratio was found between the subgroups classified by the concomitant use of VPA or amiodarone (p = 0.002). However, there were no significant correlations between the PB C/D ratio, dosage formulation, and administration route.
Conclusions: The most influential factor on the PB C/D ratio was the concomitant use of VPA or amiodarone with PB. This result could provide an important perspective in pediatric drug therapy where elixir and powder formulations are administered via the oral route and enteral tube.
Keywords: Elixir; Pediatric care; Phenobarbital; Powder; Serum concentration.
Conflict of interest statement
All authors declare that they have no competing interests.
Figures
Similar articles
-
Influence of coadministered antiepileptic drugs on serum phenobarbital concentrations in epileptic patients: quantitative analysis based on a suitable transforming factor.Biol Pharm Bull. 2004 Dec;27(12):2000-5. doi: 10.1248/bpb.27.2000. Biol Pharm Bull. 2004. PMID: 15577220
-
[Influence of coadministered antiepileptic drugs on serum antiepileptic drug concentrations in epileptic patients -quantitative analysis based on suitable transforming factor].Yakugaku Zasshi. 2004 Jul;124(7):443-50. doi: 10.1248/yakushi.124.443. Yakugaku Zasshi. 2004. PMID: 15235228 Review. Japanese.
-
Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication.Ther Drug Monit. 1996 Oct;18(5):523-31. doi: 10.1097/00007691-199610000-00001. Ther Drug Monit. 1996. PMID: 8885114 Clinical Trial.
-
Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy.Front Pediatr. 2021 Jan 20;8:599044. doi: 10.3389/fped.2020.599044. eCollection 2020. Front Pediatr. 2021. PMID: 33553069 Free PMC article.
-
Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.Clin Pharmacokinet. 1995 Oct;29(4):257-86. doi: 10.2165/00003088-199529040-00005. Clin Pharmacokinet. 1995. PMID: 8549027 Review.
Cited by
-
Analysis of Adverse Events Following Phenobarbital Administration for Pediatric Patients Categorized by One-Year Age Increments Using the U.S. Food and Drug Administration Adverse Event Reporting System.Cureus. 2024 Mar 18;16(3):e56418. doi: 10.7759/cureus.56418. eCollection 2024 Mar. Cureus. 2024. PMID: 38638715 Free PMC article.
References
-
- Hauptmann A. Luminal bei epilepsie. Munch Med Wochenschr. 1912;59:1907–1909.
-
- Tokiwa C, Nakajima M. The high blood concentration of phenobarbital after a change to elixir from powder. The Japanese Journal of Developmental Pharmacology and Therapeutics. 2018;31:50–53.
LinkOut - more resources
Full Text Sources
Other Literature Sources